Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” has been approved for once every four weeks intravenous maintenance dosing by the Medicines and Healthcare products Regulatory Agency in the United Kingdom.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
- Biogen upgraded to Buy from Hold at Stifel
- Biogen’s Hold Rating: Balancing Promising Growth with Revenue Challenges and Infrastructure Development
- Biogen to highlight progress in rare kidney disease at ASN Kidney Week
- Biogen price target raised to $157 from $155 at Bernstein